Clinical Trial Update: Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating intraoperative carbetocin to reduce blood loss during hysteroscopic myomectomy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hysteroscopic Myomectomy-related Bleeding
• Uterine Fibroids

Drugs mentioned

• Carbetocin (carbetocin)

Snippet

Sponsor: Mansoura University Hospital | Conditions: Myoma;Uterus | Phase 4 | Status: COMPLETED